

SenzaGen Q4 - Leaving Q4 behind and looking forward to a new year

Redeye provides an update following SenzaGen's Q4 2024 report. The sales during the quarter were disappointing, although we maintain that the long-term investment case remains intact. We have made sales estimate adjustments, which is the main reason for our lowered fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[SenzaGen Q4 - Leaving Q4 behind and looking forward to a new year](#)